Cleveland Clinic
Tenaya Therapeutics Doses First Hypertrophic Cardiomyopathy Patient in Gene Therapy Trial
Tenaya's first-in-human Phase Ib trial of TN-201, a gene therapy for MYBPC3-linked HCM, is underway at the Cleveland Clinic.
In Brief This Week: HuidaGene Therapeutics, Duality Biologics, Anixa Biosciences
News items for the week of Aug. 7, 2023.
Patients Are Dying Waiting for Pluvicto, but Novartis Can't Make More Pending Facility Approval
Premium
Novartis has admitted it underestimated demand for the radiopharmaceutical, though the FDA's approval of a US-based manufacturing facility may provide some relief by summer.
Researchers at the Cleveland Clinic and beyond are applying biomarker strategies to a treatment modality that has historically missed out on precision oncology advances.
Cancer Centers Nudge Oncologists Toward DPYD Testing as PGx Supporters Push For Guidelines Change
Premium
Several institutions, swayed by PGx experts and advocates, are setting up DPYD testing to avoid deadly chemo toxicities in patients even though the NCCN and FDA don't back it.
Jun 22, 2020